circadian rhythm is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-14. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
=== Lifestyle === A high-stress lifestyle causes an increase in the level of catecholamines, which have also been associated with the development of cellulite. Inactivity can cause vascular stasis, forming cellulite. Excessive carbohydrate consumption may also be related to cellulite in some instances.
itself should increase with temperature and be independent of density at fixed temperature. In fact, both of these predictions persist in more sophisticated treatments, and accurately describe experimental observations. By contrast, liquid viscosity typically decreases with temperature. For rigid elastic spheres of diameter
Morgan William Sulzer (1884), governor of New York J. Mayhew Wainwright (1884), U.S. congressman and assistant secretary of war Charles Henry Turner (1888), U.S. congressman from New York; doorkeeper of the United States House of Representatives 1891–1893 James W. Gerard (1890), U.S. ambassador to Germany 1913–1917 Victor M. Allen (1892), member of the New York State Senate John F. Carew (1893), U.S. congressman from New York Harvey R. Kingsley (1893), president pro tempore of the Vermont State Senate Edward Lazansky (1895), secretary of state of New York Carl L. Alsberg (1896), 2nd commissioner of Food and Drugs, head of the Food and Drug Administration 1912–1921 Lewis Einstein (1898), U.S. ambassador to Czechoslovakia and U.S. ambassador to Costa Rica John Purroy Mitchel (1899), mayor of New York City Montgomery Schuyler Jr. (1899), U.S. minister to El Salvador and U.S. minister to Ecuador Charles H. Tuttle (1899), U.S. attorney for the Southern District of New York and 1930 Republican nominee for governor of New York Henry W. Shoemaker (1901), folklorist, historian, diplomat; U.S. ambassador to Bulgaria 1930–1933 Martin C. Ansorge (1903), U.S. congressman from New York Stanley M. Isaacs (1903), Manhattan borough president 1938–1942 Allen J. Bloomfield (1094), member of the New York State Assembly and the New York State Senate Fred Biermann (1905), U.S. congressman from Iowa John Collier (1906), U.S. commissioner of Indian Affairs Meyer Robert Guggenheim* (1907), U.S. ambassador to Portugal 1953–1954, grandson of Meyer Guggenheim Joseph C.
== United Kingdom == The Public Health Laboratory Service (PHLS) was established as part of the National Health Service in 1946. An Emergency Public Health Laboratory Service was established in 1940 as a response to the threat of bacteriological warfare. There was originally a central laboratory at Colindale and a network of regional and local laboratories. By 1955 there were about 1000 staff. These laboratories were primarily preventive with an epidemiological focus. They were, however, in some places located with hospital laboratories which had a diagnostic focus. The PHLS was replaced by the Health Protection Agency in 2003; the HPA was disbanded and in its stead was constituted Public Health England, which later became the UK Health Security Agency in 2021.
Post-translational modifications can incorporate more complex, large molecules into the folded protein structure. One common example of this is glycosylation, the addition of a polysaccharide molecule, which is widely considered to be most common post-translational modification. In glycosylation, a polysaccharide molecule (known as a glycan) is covalently added to the target protein by glycosyltransferases enzymes and modified by glycosidases in the endoplasmic reticulum and Golgi apparatus. Glycosylation can have a critical role in determining the final, folded 3D structure of the target protein. In some cases glycosylation is necessary for correct folding. N-linked glycosylation promotes protein folding by increasing solubility and mediates the protein binding to protein chaperones. Chaperones are proteins responsible for folding and maintaining the structure of other proteins. There are broadly two types of glycosylation, N-linked glycosylation and O-linked glycosylation. N-linked glycosylation starts in the endoplasmic reticulum with the addition of a precursor glycan. The precursor glycan is modified in the Golgi apparatus to produce complex glycan bound covalently to the nitrogen in an asparagine amino acid. In contrast, O-linked glycosylation is the sequential covalent addition of individual sugars onto the oxygen in the amino acids serine and threonine within the mature protein structure.
Sources: en.wikipedia.org
Studies of Sue found a broken and healed fibula and tail vertebrae, scarred facial bones and a tooth from another Tyrannosaurus embedded in a neck vertebra, providing evidence for aggressive behavior. In 1992, William Abler suggested that Tyrannosaurus may have had infectious saliva used to kill its prey. Abler observed that the serrations (tiny protuberances) on the cutting edges of the teeth are closely spaced, enclosing little chambers, which he argued trapped pieces of carcass with bacteria, giving Tyrannosaurus a deadly, infectious bite, as the Komodo dragon was mistakenly thought to have. Jack Horner and Don Lessem, in a 1993 popular book, questioned Abler's hypothesis, arguing that Tyrannosaurus's tooth serrations as more like cubes in shape than the serrations on a Komodo monitor's teeth, which are rounded. The basis for an infectious bite in Tyrannosaurus was further undermined when it was found Komodo dragons do not actually have an infectious bite nor hunt by biting prey and tracking it as it weakens. Tyrannosaurus probably primarily processed carcasses with lateral shakes of the head, like crocodilians. The head was not as maneuverable as the skulls of allosauroids, due to flat joints of the neck vertebrae. Studies on hadrosaur vertebrae from the Hell Creek Formation that were punctured by the teeth of what appears to be a late-stage juvenile Tyrannosaurus indicate that despite lacking the bone-crushing adaptations of the adults, young individuals were still capable of using the same bone-puncturing feeding technique.
PUFA-fortified foods available on the market have been increasing since epidemiological and clinical researches have revealed possible effects of PUFA on brain development and curative and/or preventive effects on cardiovascular disease. However, PUFA are very labile and easily oxidizable, thus the maximum beneficial effects of PUFA supplements may not be obtained if they contain significant amounts of toxic OαβUAs, which as commented on above, are being considered as possible causal agents of numerous diseases. Special attention must also be paid to cooking oils used repeatedly in catering and households because in those processes very high amounts of OαβUAs are generated and they can be easily absorbed through the diet.
== Production and release == Long Story Short was created by Raphael Bob-Waksberg, the creator of BoJack Horseman, who was also the executive producer of Tuca & Bertie and Undone. Long Story Short was commissioned as a series in August 2024. Bob-Waksberg serves as the showrunner, and the show is executive-produced by Bob-Waksberg, Noel Bright, and Steven A. Cohen. The production companies are The Tornante Company and ShadowMachine. The main voice cast includes Ben Feldman, Abbi Jacobson, Max Greenfield, Lisa Edelstein, Paul Reiser, Angelique Cabral, and Nicole Byer. Each episode's credits contain the disclaimer "This Program Was Made By Humans", denoting generative AI was not used in production. Shortly before the show's release, it was renewed for a second season. Long Story Short premiered on Netflix on August 22, 2025.
== Real-life analogues == The phase transitions without any thermal effect and into the state of lower entropy described in the book are purely fictional and impossible according to current theories of physics. In the assumption that the phase transition was described inaccurately and has thermal effects (which were not described within the novel), it would have happened without any outside intervention. The initial seed being nucleated spontaneously was due to fluctuations that are always present, the same way that the ordinary liquid-solid transitions happen. Supercooling is only possible when nucleation cannot occur, which is difficult in normal circumstances due to natural impurities in water. While multiple polymorphs of ice exist, none have the properties described in the novel, and none are stable at standard temperature and pressure. The real Ice IX has none of the properties of Vonnegut's creation, and can exist only at extremely low temperatures and high pressures. Ice VII is stable at room temperature, but only under very high pressures. The ice-nine-like phenomenon has occurred with a few other kinds of crystals, called "disappearing polymorphs". In these cases, a new variant of a crystal has been introduced into an environment, replacing many of the older form crystals with its own form. One example is the anti-AIDS medicine ritonavir, where the newer polymorph destroyed the effectiveness of the drug in solid form, requiring a change to the less efficacious liquid form.
Sources: en.wikipedia.org
=== FTIR as detector in chromatography === The speed of FTIR allows spectra to be obtained from compounds as they are separated by a gas chromatograph. However this technique is little used compared to GC-MS (gas chromatography-mass spectrometry) which is more sensitive. The GC-IR method is particularly useful for identifying isomers, which by their nature have identical masses. Liquid chromatography fractions are more difficult because of the solvent present. One notable exception is to measure chain branching as a function of molecular size in polyethylene using gel permeation chromatography, which is possible using chlorinated solvents that have no absorption in the area in question.
The presentation of amyloidosis is broad and depends on the site of amyloid accumulation. The kidney and heart are the most common organs involved. Amyloid deposition in the kidney often involve the glomerular capillaries and mesangial regions, affecting the organ's ability to filter and excrete waste and retain plasma protein. This can lead to high levels of protein in the urine (proteinuria) and nephrotic syndrome. Several types of amyloidosis, including the AL and AA types, are associated with nephrotic syndrome. Approximately 20% and 40–60% of people with AL and AA amyloidosis respectively progress to end-stage kidney disease requiring dialysis.
An estimated 160 TBq (about 250 kg) of technetium-99 was released into the environment by atmospheric nuclear tests. The amount of technetium-99 from civilian nuclear power released into the environment up to 1986 is estimated to be on the order of 1000 TBq (about 1600 kg), primarily by outdated methods of nuclear fuel reprocessing; most of this was discharged into the sea. In recent years, reprocessing methods have improved to reduce emissions, but the Sellafield plant, which operated until 2022, released an estimated 550 TBq (about 900 kg) from 1995–1999 into the Irish Sea; afterward the amount was limited by regulation to 90 TBq (about 140 kg) per year.
=== Strategies === A long-acting insulin is used to approximate the basal secretion of insulin by the pancreas, which varies in the course of the day. NPH/isophane, lente, ultralente, glargine, and detemir may be used for this purpose. The advantage of NPH is its low cost, the fact that you can mix it with short-acting forms of insulin, thereby minimizing the number of injections that must be administered, and that the activity of NPH will peak 4–6 hours after administration, allowing a bedtime dose to balance the tendency of glucose to rise with the dawn, along with a smaller morning dose to balance the lower afternoon basal need and possibly an afternoon dose to cover evening need. A disadvantage of bedtime NPH is that if not taken late enough (near midnight) to place its peak shortly before dawn, it has the potential of causing hypoglycemia. One theoretical advantage of glargine and detemir is that they only need to be administered once a day, although in practice many people find that neither lasts a full 24 hours. They can be administered at any time during the day as well, provided that they are given at the same time every day. Another advantage of long-acting insulins is that the basal component of an insulin regimen (providing a minimum level of insulin throughout the day) can be decoupled from the prandial or bolus component (providing mealtime coverage via ultra-short-acting insulins), while regimens using NPH and regular insulin have the disadvantage that any dose adjustment affects both basal and prandial coverage.
=== Background === After United States diplomatic cables leak, Russian Reporter magazine published the dispatches sent by then US Ambassador to Georgia John F. Tefft during the war from Tbilisi. The cables stated that the conflict was not the aim of Georgians, but they were drawn into it by South Ossetians. Some news agencies, such as Russian Rosbalt, reported that according to the leaked documents, Russia started the war in South Ossetia. However, the same cables were assessed differently by several Russian commentators, who said that this proved that the Georgians started the war. Russky Reporter was found to have possibly published hoax cables or misinterpretations. Director of the Georgian Security Analysis Center David J. Smith commented that the cables proved that Russia started the war.
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.